Adamantinoma Epidemiology Forecast

• Adamantinoma is a rare, low-grade malignant bone tumor that accounts for less than 1% of all primary bone cancers. It most commonly affects the diaphysis (shaft) of the tibia (shinbone), with the fibula being the second most frequent site. Other, much rarer locations include the ulna, femur, humerus, radius, ribs, tarsal and metatarsal bones, and even extraskeletal soft tissue.
• Adamantinoma is a biphasic tumor, characterized by clusters of epithelial cells within a fibrous (osteofibrous) stroma. There are two main types: classic adamantinoma (dominant epithelial component) and differentiated (osteofibrous-like) adamantinoma, which more closely resembles osteofibrous dysplasia.
• Adamantinoma is extremely rare, representing less than 0.5% of all primary skeletal tumors.
• The tumor typically affects young adults, most commonly between ages 20 and 40, with a slight male predominance.
• Adamantinomas have a mortality rate of 6% to 18% and a metastasis frequency of 12% to 29% due to their local aggressiveness and metastatic potential.
• The long-term outlook is generally favorable in adamantinoma, with a ~10-year survival rate of about 85% if wide surgical margins are achieved. Prognosis worsens with incomplete resection.

DelveInsight’s “Adamantinoma Epidemiology Forecast – 2034” report delivers an in-depth understanding of adamantinoma, historical and forecasted epidemiology of adamantinoma in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Adamantinoma Epidemiology Understanding

Adamantinoma Overview

Adamantinoma is a rare, low-grade malignant bone tumor that primarily affects the long bones, most commonly the tibia. It is characterized by a slow-growing, locally aggressive behavior with a potential for late recurrence and, rarely, distant metastasis. Histologically, adamantinoma shows a biphasic pattern composed of epithelial cells forming nests and cords within a fibrous stroma, which distinguishes it from other bone tumors. It typically presents in young to middle-aged adults and may cause pain, swelling, or deformity in the affected limb. Due to its indolent course, diagnosis is often delayed, and the tumor can sometimes be misdiagnosed as a benign bone lesion or chronic infection. Surgical resection with wide margins is the mainstay of treatment, and long-term follow-up is necessary because of the risk of local recurrence.

Adamantinoma Diagnosis

Diagnosis of adamantinoma involves a combination of clinical evaluation, imaging studies, and histopathological examination. Patients usually present with localized pain or swelling in the tibia, prompting radiographic evaluation. On X-rays, adamantinoma typically appears as a well-defined, lytic lesion with cortical involvement and sometimes a “soap-bubble” or multilocular appearance. MRI is crucial for assessing the extent of marrow and soft tissue involvement, aiding surgical planning. Definitive diagnosis requires biopsy and microscopic examination, revealing characteristic epithelial cell nests within a fibrous or osteofibrous stroma. Immunohistochemical staining is often used to confirm epithelial differentiation, with markers such as cytokeratins being positive. Given the tumor’s rarity and overlap in radiologic features with other bone lesions like osteofibrous dysplasia, a thorough pathological assessment is critical for accurate diagnosis and appropriate management.

Further details related to diagnosis are provided in the report…

Adamantinoma Epidemiology

For the purpose of designing the patient-based model for adamantinoma, the report provides historical as well as forecasted epidemiology segmented by Total Incidence Cases, Age-specific Cases, Gender-specific Cases, Site-specific Cases and Treated Cases of Adamantinoma in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.

• According to secondary research, ~55% of adamantinoma cases occurred in individuals aged ≤30 years, while ~45% were in those over 30 years of age.
• Adamantinoma occurs in long tubular bones in ~97% of cases, mainly in the diaphysis. The tibia is the most common site about 80–85%, with less frequent involvement of the femur, fibula, humerus, radius, ulna, and rarely the spine, ribs, carpal, metatarsal bones, or calcaneum.
• Adamantinoma shows a slight male predominance, with reported male-to-female ratios approximately 5:4.
• According to the literature, adamantinoma has an excellent prognosis, with 5-year survival rates ranging from 85% to 95%, and 10-year survival rates reported at approximately 85%.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease incidence.

DelveInsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Centers such as the Massachusetts General Hospital, University of Cologne, Chu Brest - Hospital Morvan, and others were contacted. Their opinion helps understand and validate current disease incidence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

As per the KOLs from the US Adamantinoma is a slow-growing but locally aggressive tumor that often presents as a painless swelling or lump, which can lead to delayed diagnosis. It's important to seek timely and accurate evaluation, as there is a risk of local recurrence and potential for metastasis, particularly to the lungs.

As per the KOLs from Italy, multidisciplinary management is crucial for optimal outcomes. Diagnosis typically involves a combination of clinical assessment, imaging (X-ray, MRI, CT), and a confirmatory biopsy, with histological analysis being essential to distinguish adamantinoma from similar lesions such as osteofibrous dysplasia.

As per the KOLs from Japan, early referral to specialized sarcoma centers and coordinated care by a multidisciplinary team including orthopedic oncologists, pathologists, radiologists, and specialist nurses are essential to improving patient prognosis and quality of life.

Scope of the Adamantinoma Epidemiology Report

• The report covers a segment of executive summary, descriptive overview of adamantinoma, explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Adamantinoma Epidemiology Report Insights

• Adamantinoma Patient Population
• Country-wise Epidemiology Distribution
• Total Incidence Cases of Adamantinoma
• Age-specific Cases of Adamantinoma
• Gender-specific Cases of Adamantinoma
• Site-specific Cases of Adamantinoma
• Treated Cases of Adamantinoma

Adamantinoma Epidemiology Report Key Strengths

• 10 years Forecast
• The 7MM Coverage
• Adamantinoma Epidemiology Segmentation

Adamantinoma Epidemiology Report Assessment

• Current Diagnostic Practices Patient Segmentation

Adamantinoma Epidemiology Insights

• What are the disease risk, burdens, and unmet needs of adamantinoma? What will be the growth opportunities across the 7MM concerning the patient population of adamantinoma?
• What is the historical and forecasted adamantinoma patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Why is the incidence cases of adamantinoma in Japan lower than the US?
• Which country has a high patient share for adamantinoma?

Reasons to Buy Adamantinoma Epidemiology Forecast Report

• Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the adamantinoma incidence cases in varying geographies over the coming years.
• A detailed overview of age, gender, and site-specific incidence cases of adamantinoma, and incidence of adamantinoma based on diagnostic imaging modality and regional population differences, since variations in imaging sensitivity and demographic factors substantially influence detection rates.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1.           What is the forecast period covered in the report?

The adamantinoma epidemiology report for the 7MM covers the forecast period from 2025 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2.           How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.